Business
Artiva is a clinical-stage biotechnology company developing natural killer cell-based therapies for autoimmune diseases and cancers.
Artiva revenue fell to zero, the net loss widened to $83.9M, and free cash flow fell to -$79.3M.
The read at a glance✓ Audited against SEC data
- Business mix — NK cell therapiesNote
- Revenue — Revenue fell to zeroWatch
- Profitability — Net loss widened to $83.9MWatch
- Cash — FCF fell to -$79.3MWatch
- Balance sheet — Equity fell 41.1%Watch
- Insiders — 0 buys / 4 sellsWatch
- Accounting — Altman-Z distressWatch
Leadership changes
From Artiva Biotherapeutics, Inc.'s own filings, the day they're filed.
- Thad Huston · Chief Financial Officer · departureeff. 2026-05-22
- Diego Miralles · President · departureeff. 2026-05-18
- Thad Huston · Chief Financial Officer · appointmenteff. 2026-02-18
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- DEF 14A · Annual proxy (pay & governance)2026-08-03
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-05-19
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Artiva Biotherapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.